New Lifetime High Reached By Allergan (AGN)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Allergan ( AGN) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Allergan as such a stock due to the following factors:

  • AGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $304.3 million.
  • AGN has traded 38,311 shares today.
  • AGN is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AGN with the Ticky from Trade-Ideas. See the FREE profile for AGN NOW at Trade-Ideas

More details on AGN:

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The stock currently has a dividend yield of 0.2%. AGN has a PE ratio of 29.9. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

The average volume for Allergan has been 2.4 million shares per day over the past 30 days. Allergan has a market cap of $37.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.65 and a short float of 0.9% with 1.17 days to cover. Shares are up 14.6% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 2.8%. Since the same quarter one year prior, revenues rose by 14.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The current debt-to-equity ratio, 0.33, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 3.64, which clearly demonstrates the ability to cover short-term cash needs.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, ALLERGAN INC's return on equity exceeds that of both the industry average and the S&P 500.
  • ALLERGAN INC reported flat earnings per share in the most recent quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ALLERGAN INC increased its bottom line by earning $4.20 versus $3.57 in the prior year. This year, the market expects an improvement in earnings ($5.47 versus $4.20).
  • The gross profit margin for ALLERGAN INC is currently very high, coming in at 86.18%. Regardless of AGN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, AGN's net profit margin of 18.57% compares favorably to the industry average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

24 Stocks Hedge Funds Are Loving Right Now

24 Stocks Hedge Funds Are Loving Right Now

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff